Camp4 Therapeutics Corporation (CAMP)
NASDAQ: CAMP · Real-Time Price · USD
3.800
-0.290 (-7.09%)
Nov 13, 2026, 4:00 PM EST - Market closed
Camp4 Therapeutics Revenue
Camp4 Therapeutics had revenue of $1.90M in the quarter ending September 30, 2026, with 138.87% growth. This brings the company's total for the last twelve months to $5.32M, up 39.93% year-over-year. In the year 2025, Camp4 Therapeutics had annual revenue of $3.50M with 436.50% growth. That makes Camp4 Therapeutics the 39,802nd largest company in the world by revenue and 5,275th in the United States.
Revenue (ttm)
$5.32M
Revenue Growth
+39.93%
P/S Ratio
44.82
Revenue / Employee
$110,833
Employees
48
Market Cap
238.47M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.50M | 2.85M | 436.50% |
| Dec 31, 2024 | 652.00K | 302.00K | 86.29% |
| Dec 31, 2023 | 350.00K | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
CAMP News
- 5 days ago - Camp4 Therapeutics Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts
- 6 days ago - Camp4 Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 10 days ago - Camp4 Therapeutics reports Q3 EPS (37c), consensus (22c) - TheFly
- 10 days ago - CAMP4 Reports Third Quarter 2026 Financial Results and Corporate Highlights - GlobeNewsWire
- 11 days ago - Camp4 Therapeutics Quarterly report: Q3 2026 - Filings
- 11 days ago - Camp4 Therapeutics Earnings release: Q3 2026 - Filings
- 19 days ago - Camp4 Therapeutics receives CTA approval for CMP-002 in the European Union - TheFly
- 20 days ago - CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union - GlobeNewsWire